In a late-stage trial, Novavax’s prototype COVID-19 vaccine increased neutralizing antibody titers up to 34 times higher than primary vaccination among adults, with a “significant boost” against omicron variants and subvariants BA.1, BA.2 and BA.5.
Read the full post on Becker's Hospital Review - Healthcare News
